JP2010536759A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536759A5
JP2010536759A5 JP2010521043A JP2010521043A JP2010536759A5 JP 2010536759 A5 JP2010536759 A5 JP 2010536759A5 JP 2010521043 A JP2010521043 A JP 2010521043A JP 2010521043 A JP2010521043 A JP 2010521043A JP 2010536759 A5 JP2010536759 A5 JP 2010536759A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
avpal variant
use according
stabilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536759A (ja
JP5584120B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009765 external-priority patent/WO2009025760A2/en
Publication of JP2010536759A publication Critical patent/JP2010536759A/ja
Publication of JP2010536759A5 publication Critical patent/JP2010536759A5/ja
Application granted granted Critical
Publication of JP5584120B2 publication Critical patent/JP5584120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521043A 2007-08-17 2008-08-15 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物を用いる癌の治療方法 Active JP5584120B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
US61/066,125 2007-08-17
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (3)

Publication Number Publication Date
JP2010536759A JP2010536759A (ja) 2010-12-02
JP2010536759A5 true JP2010536759A5 (https=) 2011-10-06
JP5584120B2 JP5584120B2 (ja) 2014-09-03

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521043A Active JP5584120B2 (ja) 2007-08-17 2008-08-15 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物を用いる癌の治療方法

Country Status (23)

Country Link
US (4) US7560263B2 (https=)
EP (1) EP2175875B1 (https=)
JP (1) JP5584120B2 (https=)
CN (1) CN101803492B (https=)
AR (2) AR067972A1 (https=)
AU (1) AU2008289549B2 (https=)
BR (2) BR122018072594B8 (https=)
CA (1) CA2687028C (https=)
CL (1) CL2008002390A1 (https=)
CY (1) CY1118222T1 (https=)
DK (1) DK2175875T3 (https=)
ES (1) ES2602618T3 (https=)
HR (1) HRP20161474T1 (https=)
HU (1) HUE029510T4 (https=)
LT (1) LT2175875T (https=)
MX (1) MX2009012261A (https=)
PE (1) PE20090605A1 (https=)
PL (1) PL2175875T3 (https=)
PT (1) PT2175875T (https=)
RU (2) RU2553343C2 (https=)
SI (1) SI2175875T1 (https=)
TW (1) TWI418787B (https=)
WO (1) WO2009025760A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
AU2013295621A1 (en) * 2012-07-27 2015-03-12 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
NZ713396A (en) 2013-04-18 2020-06-26 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
US10752923B2 (en) 2014-07-14 2020-08-25 Cysbio Aps Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
LT3237621T (lt) 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
MX2019009615A (es) 2017-02-13 2019-10-14 Codexis Inc Polipeptidos dise?ados de fenilalanina amonio liasa.
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3122524A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
AU2019403323B2 (en) 2018-12-20 2026-02-26 Codexis, Inc. Human alpha-galactosidase variants
EP3923988B1 (en) 2019-02-14 2025-04-30 Som Innovation Biotech, S.A. Triamterene or nolatrexed for use in the treatment of phenylketonuria
CN114585391A (zh) * 2019-08-07 2022-06-03 乐天医药生技股份有限公司 西妥昔单抗-ir700偶联物组合物
EP4501403A3 (en) 2019-08-30 2025-05-14 Société des Produits Nestlé S.A. Engineered lipase variants
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス, インコーポレイテッド 操作された酸性アルファ-グルコシダーゼバリアント
JP2023512683A (ja) 2020-02-04 2023-03-28 コデクシス, インコーポレイテッド 操作されたロイシンデカルボキシラーゼ
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
CN116897205A (zh) 2020-08-28 2023-10-17 科德克希思公司 工程化淀粉酶变体
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
CA3220735A1 (en) 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ,インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
EP0692029B1 (en) 1992-12-04 2007-05-09 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in therapy
DK75593D0 (https=) 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ(faah)の結晶形
WO2006034373A2 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) * 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Similar Documents

Publication Publication Date Title
JP2010536759A5 (https=)
JP6966678B2 (ja) Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害
CN102459647B (zh) 与干扰素-α应答有关的遗传标记
Kouretova et al. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication
RU2009141987A (ru) Композиции прокариотической фенилаланин-аммиак-лиазы и способы лечения рака с использованием таких композиций
Kopp et al. Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure− activity relationship of daptomycin and A54145
JP6928324B1 (ja) 滑膜細胞増殖抑制剤、関節腔注入剤、及び食品組成物
Sidhu et al. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia
JP2021004268A (ja) 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ
JP2009527498A (ja) 癌におけるcaPCNA相互作用のペプチドによる抑制
KR101746160B1 (ko) 결핵균 독소-항독소 체계를 표적으로 하는 항생 펩타이드 및 이의 용도
CN107001419A (zh) 神经变性障碍
WO2021212056A2 (en) Engineered interleukin-22 polypeptides and uses thereof
Gámez et al. Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CN106232810A (zh) 新的治疗
Tan et al. De novo discovery of a noncovalent cell-penetrating bicyclic peptide inhibitor targeting SARS-CoV-2 main protease
Li et al. Emerging discoveries on the role of TRIM14: from diseases to immune regulation
Sharpe et al. Role of Ras isoforms in the stimulated proliferation of human renal fibroblasts in primary culture
KR20200012894A (ko) 펩타이드 및 항바이러스제로서의 이의 용도
Park et al. Selective inhibition of human inducible nitric oxide synthase by S‐alkyl‐L‐isothiocitrulline‐containing dipeptides
ES2648487T3 (es) Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso
US20240228543A1 (en) Cyclic peptide inhibitors of usp22
JP2004513631A5 (https=)
Jurkova et al. Human Cyclophilins—An Emerging Class of Drug Targets